Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

• Published in: The lancet oncology Vol. 23; no. 10; pp. 1261 - 1273
• Main Authors: Subbiah, Vivek, Wolf, Jürgen, Konda, Bhavana, Kang, Hyunseok, Spira, Alexander, Weiss, Jared, Takeda, Masayuki, Ohe, Yuichiro, Khan, Saad, Ohashi, Kadoaki, Soldatenkova, Victoria, Szymczak, Sylwia, Sullivan, Loretta, Wright, Jennifer, Drilon, Alexander
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2022; Elsevier Limited
• Subjects: Adverse events; Alanine; Alanine Transaminase; Aspartate aminotransferase; Aspartate Aminotransferases; Biomarkers; Carcinoma, Non-Small-Cell Lung - drug therapy; Disease; Drug dosages; Enzyme inhibitors; FDA approval; Health facilities; Hematology, Oncology, and Palliative Medicine; Humans; Laboratories; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical research; Non-small cell lung carcinoma; Oncology; Oral administration; Patients; Population; Protein Kinase Inhibitors - adverse effects; Proto-Oncogene Proteins c-ret - genetics; Pyrazoles; Pyridines; Regulatory approval; Response rates; Safety; Solid tumors; Thyroid cancer; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - genetics; Tumors; United States > US

Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy and safety of selpercatinib in a diverse group of p...